Lecture 10 – Plasmalogens and the Epidemiology of Alzheimer’s Dementia and Death: Breaking Alzheimer’s – The Definitive Lecture Series

Plasmalogens were first discovered in 1924, almost 100 years ago. Peroxisomes, the intracellular organelle where plasmalogens are made, were discovered in 1960. The rare cerebrohepatorenal syndrome called Zellweger’ syndrome was first identified in the mid 1960’s. This is a very serious disease. Children with this disease typically die within 6 months of birth. In 1973 it was discovered that Zellweger’ syndrome was caused by a lack of peroxisomes. In 1979 it was discovered that plasmalogens were exclusively made in peroxisomes and in 1983 it was shown that children with Zellweger’ syndrome had tissue plasmalogen levels less than 10% of the levels in normal children. Later in the 1980’s children with other rare peroxisomal diseases were observed to have very low plasmalogen levels and in one such disease, Rhizomelic Chondrodysplasia Punctata, the clinical phenotype in some children is exclusively due to plasmalogen deficiencies. Relatively recently, in 2014, it was shown that birth defects that only mildly affect plasmalogen biosynthesis can cause RCDP. These clinical experiences exemplify the importance of sufficient plasmalogen levels for human health. 

To access the FREE seminars with full presentations and videos please visit Dr. Goodenowe’s resource site here. This is the article for Lecture 10 – Plasmalogens and the Epidemiology of Alzheimer’s Dementia and Death, of Breaking Alzheimer’s – The Definitive Lecture Series.

In the late 1990’s post-mortem studies began to reveal that plasmalogen levels were selectively depleted in the brain in persons with dementia. These results were confirmed by multiple researchers over the course of a decade. However, the prevailing hypothesis at the time was that persons with dementia were experiencing increased levels of oxidative stress that was being caused by Alzheimer’s pathology.  

In 1999, using ion cyclotron mass spectrometry, Dr. Goodenowe invented and subsequently patented a comprehensive biochemical analysis technology that enabled him to simultaneously measure thousands of biochemicals in biological samples. Using this technology, Dr. Goodenowe built the world’s most advanced mass spectrometry laboratory and applied this technology to a plethora of research studies from gene function analyses to large clinical trials. In 2005, Dr. Goodenowe performed analyses on serum samples collected from persons with varying degrees of cognitive impairment. When he interpreted the data, he discovered that blood plasmalogen levels were decreased in persons with dementia and the severity of the deficiency was correlated to the severity of the dementia. This discovery meant that the current hypothesis regarding the decrease in brain plasmalogens was wrong. A systemic depletion of plasmalogens was causing dementia, not a local pathology-dependent oxidative stress depletion. 

The ramifications of this discovery was then and continues to be now, immense. We are just now starting to see the effects. Independent researchers from around the world have since confirmed these findings. However, at the time, a discovery of this magnitude had to be vigorously validated and confirmed. To do this, Dr. Goodenowe collaborated with multiple clinical research groups from around the world each of which had clinical samples representing a separate unique aspect of Alzheimer’s and dementia research. Dr. John Flax from San Diego had a large and very well characterized cohort of persons with highly resolved cognition measurements. Dr. Larry Sparks from Sun City Arizona had a cohort of persons where he had collected blood samples at time of death and had detailed post-mortem pathology measurements. Dr. Alan Lerner from Case-Western University in Cincinnati had blood samples that were collected from persons with clinical dementia between 0.6-13 years prior to their death and which were pathologically confirmed to have Alzheimer’s at death. Dr. Masatoshi Takeda from Osaka, Japan had blood samples from Japanese persons with and without dementia. In total, comprehensive plasmalogen analyses were performed on over 400 clinically demented and over 350 non-demented persons. These results were published in 2007 in the Journal of Lipid Research. 

Since the publication of these definitive results, Dr. Goodenowe has continued to expand on these findings with larger studies with more detailed longitudinal outcomes such as the relationship with the APOE genotype, the risk of converting from a non-demented status to a demented status and the risk of death. These additional studies are detailed in Dr. Goodenowe’s 2021 book, Breaking Alzheimer’s

So, what is the full story on the relationship between blood and brain plasmalogen levels and cognition, and death? Join Dr. Goodenowe for Lecture 10 – Plasmalogens and the Epidemiology of Alzheimer’s and dementia and find the answers to these questions and many more.  In Lecture 10 – Plasmalogens and the Epidemiology of Alzheimer’s and dementia, Dr. Goodenowe explains the relevant research and literature relating to the relationship between blood and brain plasmalogen levels, dementia, and death. The lectures integrate Dr. Goodenowe’s own research and over 50 years of research from leading researchers from around the world. 

Share on facebook
Share on twitter
Share on linkedin
Your privacy is important to us.

To better protect your privacy, we provide this notice explaining our online information practices and the choices you can make about the way your information is collected and used. To make this notice easy to find, we make it available on our homepage and at every point where personally identifiable information may be requested.

Collection of Personal Information

When visiting drdayangoodenowe.com, the IP address used to access the site will be logged along with the dates and times of access. This information is purely used to analyze trends, administer the site, track users’ movement and gather broad demographic information for internal use. Most important, any recorded IP addresses are not linked to personally identifiable information.

Links to Third-Party Websites
We have included links on this site for your use and reference. We are not responsible for the privacy policies on these websites. You should be aware that the privacy policies of these sites may differ from our own.
Our Use of Google Analytics
The Dr. Dayan Goodenowe website uses the Google Analytics tool to measure traffic on the site and traffic to the site via our online advertising. This includes using certain Advertising Features, which enable Google Analytics to collect data about users via Google advertising cookies and identifiers, in addition to anonymous data collected through the standard Google Analytics implementation. These Advertising Features, which drdayangoodenowe.com may or may not be currently using, include:
  • Remarketing with Google Analytics. This allows us to display our ads to you as you search online for similar businesses.
  • Google Display Network Impression Reporting, which shows which of our ads users click on.
  • Google Analytics Demographics and Interest Reporting, which provides information about the age and gender of site users, along with the interests they express in their online travel and purchasing activities.
  • Integrated services that require Google Analytics to collect data via advertising cookies and identifiers.
We do not merge personally identifiable information with non-personally identifiable information collected through any Google advertising product or feature unless we have obtained robust notice of, and the user’s prior affirmative (i.e., opt-in) consent to, that merger. These Advertising Features, which drdayangoodenowe.com may or may not be currently using, include:
Opt Out

There are several ways to opt out of interest-based advertising and/or all tracking related to Google Analytics and its advertising features.

You can opt out of interest-based ads by Google through Ads Settings. When you opt out, you’ll still see ads but they may not be related to factors such as your interests, previous visits to other websites, or demographic details. Obtain instructions here.

The Network Advertising Initiative offers a free tool that allows users to opt out from receiving interest-based ads from some or all NAI participating member companies that use cookies on your computer browser to collect data for interest-based advertising. Find information about it here.

Website visitors can totally block Google Analytics with the Google Analytics opt-out browser add-on (click to download). This add-on instructs the Google Analytics JavaScript (ga.js, analytics.js, and dc.js) running on websites to prohibit their information from being used by Google Analytics. Using the Google Analytics opt-out plug-in will not prevent site owners from using other tools to measure site analytics. Learn more about about the opt-out and how to properly install the browser add-on here.

Changes to this Privacy

Statement The contents of this statement may be altered at any time, at our discretion.

If you have any questions regarding the privacy policy of drdayangoodenowe.com then you may contact us at info@drdayangoodenowe.com

terms of use
Welcome to our website. If you continue to browse and use this website, you are agreeing to comply with and be bound by the following terms and conditions of use, which together with our privacy policy govern drdayangoodenowe.com’s relationship with you in relation to this website. If you disagree with any part of these terms and conditions, please do not use our website.

The term ‘drdayangoodenowe.com’ or ‘us’ or ‘we’ refers to the owner of the website whose registered office is:

40880 County Center Drive
Suite R
Temecula, CA 92591, USA

The term ‘you’ refers to the user or viewer of our website.

The use of this website is subject to the following terms of use:

The content of the pages of this website is for your general information and use only. It is subject to change without notice.

Neither we nor any third parties provide any warranty or guarantee as to the accuracy, timeliness, performance, completeness or suitability of the information and materials found or offered on this website for any particular purpose. You acknowledge that such information and materials may contain inaccuracies or errors and we expressly exclude liability for any such inaccuracies or errors to the fullest extent permitted by law.

Your use of any information or materials on this website is entirely at your own risk, for which we shall not be liable. It shall be your own responsibility to ensure that any products, services or information available through this website meet your specific requirements.

This website contains material which is owned by or licensed to us. This material includes, but is not limited to, the design, layout, look, appearance and graphics. Reproduction is prohibited other than in accordance with the copyright notice, which forms part of these terms and conditions.

All trademarks reproduced in this website, which are not the property of, or licensed to the operator, are acknowledged on the website.

Unauthorized use of this website may give rise to a claim for damages and/or be a criminal offence.

From time to time, this website may also include links to other websites. These links are provided for your convenience to provide further information. They do not signify that we endorse the website(s). We have no responsibility for the content of the linked website(s).

Your use of this website and any dispute arising out of such use of the website is subject to the laws of Canada and USA.

We use cookies to make this site as useful as possible. They are small text files we put in your browser to track usage of our site but they don’t tell us who you are. If you want to delete any cookies that are already on your computer, please refer to the instructions for your file management software to locate the file or directory that stores cookies.

This site is not a part of the Facebook website or Facebook Inc. Additionally, this site is not endorsed by Facebook in any way. FACEBOOK is a trademark of FACEBOOK, Inc.